Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Expands as 80+ Companies Driving Innovation in the Therapeutics | DelveInsight

AI Briefing

• – Idiopathic Pulmonary Fibrosis (IPF) treatment pipeline expanding with 80+ companies, multiple novel therapies in various stages of development, including small molecules, biologics, and combination regimens.
• – Several mid-to-late-stage trials investigating new mechanisms and targets, including fibrosis pathways and inflammatory processes.
• – Key players in IPF therapeutics include Novartis, GSK, Pfizer, and Vertex Pharmaceuticals, with several upcoming regulatory approvals expected in the next few years.